Contact
searchSearch
HMP Global
Login

News

News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
Alicia Latham, MD
Conference Coverage
Using Pap-Derived ctDNA for Early Detection of Endometrial Cancer
06/05/2025
Alicia Latham, MD
Alicia Latham, MD, discusses results from a feasibility study which demonstrated the clinical promise of using pap-derived ctDNA to detect endometrial cancer.
Alicia Latham, MD, discusses results from a feasibility study which demonstrated the clinical promise of using pap-derived ctDNA to detect endometrial cancer.
Alicia Latham, MD, discusses...
06/05/2025
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Metformin Added to Letrozole and Abemaciclib Shows Promise in ER-Positive Endometrial Cancer
06/03/2025
Emily Estrada
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to letrozole and abemaciclib induces deeper responses and prolonged PFS vs letrozole and abemaciclib alone in recurrent ER-positive endometrial cancer, according to results from a phase 2 trial.
The addition of metformin to...
06/03/2025
Oncology
Conference Coverage
Durvalumab With or Without Olaparib Plus Chemotherapy for Patients With Mismatch Repair Proficient Endometrial Cancer
03/19/2025
Allison Casey
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the DUO-E trial found chemotherapy plus durvalumab with or without olaparib improved the progression-free survival across multiple subgroups of patients with mismatch proficient advanced or recurrent endometrial...
Exploratory analyses from the...
03/19/2025
Oncology
Conference Coverage
Addition of Metformin to Letrozole and Abemaciclib Improves Response, PFS Among Patients With Recurrent Estrogen Receptor-Positive Endometrial Cancer
03/17/2025
Allison Casey
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a phase 2 trial, the addition of metformin to letrozole and abemaciclib improved the response and progression-free survival for estrogen receptor-positive recurrent endometrial cancer.
According to results from a...
03/17/2025
Oncology
Conference Coverage
Endometrial Sampling Among Patients Who Underwent Transvaginal Ultrasound for Postmenopausal Bleeding
03/17/2025
Allison Casey
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found that two-thirds of patients did not receive a timely endometrial sampling as indicated by a thick endometrium or inadequate viewing upon transvaginal ultrasound for postmenopausal bleeding.
A large multicenter study found...
03/17/2025
Oncology
News
Pembrolizumab Plus Lenvatinib Did Not Significantly Improve Survival for Patients With Mismatch Repair-Proficient Advanced or Recurrent Endometrial Cancer
12/18/2024
Stephanie Holland
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3 LEAP-001 study demonstrated that first-line lenvatinib plus pembrolizumab did not significantly improve survival compared to lenvatinib plus chemotherapy among patients with pMMR advanced or recurrent...
Final results from the phase 3...
12/18/2024
Oncology
News
Chronic Stress May Contribute to Progression of Metastatic Endometrial Cancer
12/05/2024
Allison Casey
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated with progression of metastatic disease, particularly among postmenopausal patients with endometrial cancer and lymph node metastasis.
Chronic stress may be associated...
12/05/2024
Oncology
News
Dostarlimab Plus Chemotherapy Reduces the Risk of Progression or Death for Patients With dMMR/MSI-H Advanced or Recurrent Endometrial Cancer
11/26/2024
Stephanie Holland
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results from the RUBY trial, dostarlimab plus chemotherapy reduced the risk of progression or death among patients with mismatch repair deficient or microsatellite instability-high advanced or recurrent endometrial...
According to additional results...
11/26/2024
Oncology

Recent News

FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
FDA Alerts
Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer
05/07/2026
Stephanie Holland
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the...
05/07/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology
News
Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the...
05/07/2026
Oncology
News
ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use